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Regular Article
CLINICAL TRIALS AND OBSERVATIONS
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Key Points
• In AML with bialleleic CEBPA-
mut relapse-free survival was
improved by allogeneic and
autologous hematopoietic
stem cell transplantation.
• In relapsed patients second
complete remission rate was
high and survival was
favorable after an allogeneic
transplantation.
The clinical value of allogeneic hematopoietic stem cell transplantation (alloHSCT) and
autologous hematopoietic stem cell transplantation (autoHSCT) in the subtype of acute
myeloid leukemia (AML) with double mutant CEBPA (CEBPAdm) has remained unsettled.
Among 2983 patients analyzed for CEBPA mutational status (age 18-60 years) treated on
4 published Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group (HOVON/SAKK)
and 3 German-Austrian AML Study Group (AMLSG) protocols (2 published, 1 registered,
clinicaltrials.gov NCT00151255), 124 had AML with CEBPAdm and achieved first complete
remission (CR1). Evaluation of the clinical impact of alloHSCT and autoHSCT vs che-
motherapy was performed by addressing time dependency in the statistical analyses.
Thirty-two patients proceeded to alloHSCT from a matched related (MRD, n 5 29) or a
matched unrelated donor (MUD, n 5 3), 20 to autoHSCT in CR1 and 72 received che-
motherapy. Relapse-free survival was significantly superior in patients receiving an
alloHSCT or autoHSCT in CR1 as compared with chemotherapy (P < .001), whereas
overall survival was not different (P < .12). Forty-five patients relapsed. Of 42 patients
treated with reinduction therapy, 35 achieved a second CR (83%) and most patients (n 5 33) received an alloHSCT MRD, n 5 11;
MUD, n 5 19; haplo-identical donor, n 5 3). Survival of relapsed patients measured from date of relapse was 46% after 3 years.
Adult AML patients with CEBPAdm benefit from alloHSCT and autoHSCT; relapsed patients still have a favorable outcome after
reinduction followed by alloHSCT. (Blood. 2013;122(9):1576-1582)
Introduction
Acute myeloid leukemia (AML) with mutated CCAAT/enhancer
binding protein a (CEBPA) gene represents a provisional disease
entity in the current World Health Organization (WHO) classiﬁca-
tion in the category “AML with recurrent genetic abnormalities.”1,2
However, multiple studies demonstrated that AML with double
mutant CEBPA (CEBPAdm) could be clearly distinguished from
AML with single mutant CEBPA with respect to biological and
prognostic features.3-8 In the majority of AML with CEBPAdm, one
allele is affected by an N-terminal mutation and the second allele
carries the mutation in the C-terminus (bZIP), whereas in AML with
a single mutant CEBPA, mutations occur either in the N-terminus
or in the C-terminus of the gene.9 The previously shown favorable
impact of mutant CEBPA in various independent comprehensive
studies on prognosis10 has more recently been speciﬁcally related to
the subtype of AML with CEBPAdm.3-8
The incidence of AML with mutated (single and double) CEBPA
ranges from 7.5% to 11% of all AML patients and from about 13%
to 18% in AML exhibiting a normal karyotype.3-8,10-12 Furthermore,
the incidence of AML with mutated CEBPA in patients who are
.60 years range from 8.5%13 to 18%.14
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Young and middle aged adults (age 18-60 years) with AML and
mutated CEBPA and especially those with CEBPAdm have a
comparatively high probability of achieving a complete remission
after standard “7 1 3” induction therapy with remission rates
exceeding 90%.6,8 Treatment outcome data revealed a favorable
prognosis with an overall survival (OS) after 5 years ranging
between 50% and 70%,3-8 including different types of consolidation
therapy with intensive chemotherapy, autologous hematopoietic
stem cell transplantation (autoHSCT), and allogeneic hematopoi-
etic stem cell transplantation (alloHSCT). However, relapse still
remains the major cause of treatment failure that mainly occurs
within the ﬁrst 2 years after achieving a complete remission (CR).
This has for instance raised the question whether autoHSCT and
alloHSCT in (CR1) should be recommended in patients with this
genetic abnormality. So far, analyses according to the type of
postremission treatment in CEBPAdm AML patients have not
become available mainly due to limited patient numbers precluding
informative statistical analyses. Thus, it still remains unclear whether
the favorable prognosis of AML with CEBPAdm can be attributed
to the mutation itself irrespective of the type of applied postremission
therapy (ie, prognostic marker) or whether the favorable prognosis
is the result of a high rate of cure after autoHSCT and alloHSCT in
CR1 and after relapse (ie, predictive marker). Informative insight
into these factors could be of direct clinical relevance, as it may
guide treatment decisions on the application of autoHSCT and
alloHSCT already in CR1 or alternatively to hold back on these
approaches and reserve the option especially of an alloHSCT
as salvage only in relapsed patients. To address this question,
the Dutch-Belgian-Swiss Hemato-Oncology Cooperative Group
(HOVON/SAKK) and the German-Austrian AML Study Group
(AMLSG), as leukemia cooperative groups, performed a joint effort
on an individual-patient based meta-analysis focusing on the AML
CEBPAdm subtype in CR1. The aim was to evaluate different post-
remission strategies with a major focus on the comparison between
alloHSCT, autoHSCT, and intensive chemotherapy in a large series
of CEBPAdm AML patients in CR1. Furthermore, with an integrated
approach, we also included treatment after relapse and its impact on
outcome.
Patients and methods
Patients and treatment
All patients included in this study were recruited within 2 major leukemia
cohorts. AML patients from cohort I (n 5 3450) were enrolled in the
HOVON/SAKK trials HOVON04(A), HOVON29/SAKK30/95,15-17
HOVON42(A)/SAKK30/00, and HOVON92/SAKK30/0816-18 (infor-
mation on the trials is avaibale at www.hovon.nl). Patients received 2
successive cycles of anthracycline–cytarabine- and amsacrine–cytarabine-
based remission induction chemotherapy and, subsequently, in CR1 con-
solidation chemotherapy, autoHSCT after myeloablative therapy according to
a randomization against chemotherapy and depending on an adequate stem
cell collection,18 or alloHSCT after mainly myeloablative conditioning
depending on the availability of a matched related donor (MRD).
Cohort II (n 5 2274) comprised patients who were enrolled in the
AMLSG trials AML HD93,19 AML HD98A,20 and AMLSG 07-04
(ClinicalTrials.gov Identiﬁer: NCT00151242). Consistently throughout all
AMLSG trials, patients with AML exhibiting an intermediate-risk karyotype
with mutant CEBPA were intended to receive a double induction therapy
with idarubicin, cytarabine, and etoposide, and repetitive cycles of high-dose
cytarabine-based consolidation therapy, or, if an HLA-matched family
donor was available, an allogeneic hematopoietic stem cell transplantation
(HSCT) after a myeloablative conditioning regimen.
Patients were selected from the total cohort if they fulﬁlled all 3 of the
following criteria: (1) normal karyotype or intermediate-risk karyotype
according to EuropeanLeukemiaNet (ELN) criteria,2 (2) CEBPAdm; and
(3) CR after induction therapy. The selection process is illustrated in
Figure 1. In 90% (5147 of 5724) of the patients, information on cyto-
genetics was available. In these 5147 patients, the CEBPA mutation status
was available in 2983 (58%); of those, 137 exhibited a CEBPAdm in the
context of a normal karyotype or intermediate-risk cytogenetics (4.6%).There
were 124 patients who achieved a CR1 after induction therapy within the
different protocols (90.5% CR rate) who were included into this study.
All patients provided written informed consent in accordance with the
Declaration of Helsinki. All trials were approved by the institutional review
boards. CEBPA mutational status was identiﬁed by denaturing high-
performance liquid chromatography, polymerase chain reaction ampliﬁca-
tion followed by direct sequencing or fragment-length analysis (GeneScan)
and subsequent sequence analysis in any positive cases.4,5 Cytogenetics
and molecular analyses were performed as described before.8,10,21-23
Statistical analysis
The deﬁnition of CR and survival end points such as OS, cumulative incidence
of relapse (CIR), and death in CR (CID), as well as relapse-free survival (RFS)
were based on the recommended consensus criteria.2 Actuarial estimates were
used for the assessment of median follow-up for survival. Patient character-
istics were compared by the Kruskal-Wallis test (continuous variables) and
the Fisher’s exact test (categorical variables). CIR and CID were analyzed
according to the method of Gray.24 To address the time dependence of the
variables alloHSCT and autoHSCT, the graphical representation, according
to the method of Simon and Makuch25 was used, as well as the Mantel-Byar
test, as appropriated statistical approach in univariable analyses.26 For multi-
variable analyses, an extended Cox regression model was used according to
the method of Andersen and Gill.27 For all analyses, P < .05 was considered
statistically signiﬁcant. All statistical analyses were performed using the
statistical software Stata Statistical Software (release 12).
Results
Demographics and clinical baseline characteristics of the
study population
In this cooperative individual patient data meta-analysis, 124
CEBPAdm AML patients were included with normal karyotype or
intermediate-risk cytogenetics (ages between 18 and 60 years and
Figure 1. Flowchart on patient selection. Number of patients according to each
selection step.
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CR1 after induction therapy). The patients were selected from the
total study population treated in the HOVON/SAKK and AMLSG
prospective multicenter clinical trials recruited between 1987 and
2009 (Figure 1). Baseline characteristics and demographics for the
total cohort are shown in Table 1.
No signiﬁcant difference in OS was seen between the HOVON/
SAKK and the AMLSG CEBPAdm patient cohorts (n 5 50 vs
n 5 74, Cox test; P 5 .36); molecular and clinical variables were
comparable between the HOVON/SAKK and the AMLSGCEBPAdm
patient cohorts with the exception of platelet counts (P5 .02, lower
in AMLSG) and bone marrow blasts (P, .0001, lower in HOVON/
SAKK).
Postremission therapy, CIR, and CID in CEBPAdm patients
Distribution of postremission treatment modalities in the 124 patients
was as follows: alloHSCT, n5 32 (MRD n5 29, matched unrelated
donor [MUD] n5 3); autoHSCT, n5 20; intensive chemotherapy,
n 5 72. The median time interval from diagnosis to achievement
of CR1 was 1.1 months (range 0.36-4.11) with a trend (P 5 .053)
for a longer interval in patients who received an autoHSCT as
postremission treatment (median 1.25 months) compared with those
who received an alloHSCT (median 1.1 months) or chemotherapy
(median 1.1 months). The median time interval from CR1 to
alloHSCT and autoHSCT was 4.0 months (range 0.8-6.5) and 2.3
months (range 0.4-6.2), respectively.
In total, 45 relapses (1 after alloHSCT, 5 after autoHSCT, and
39 after intensive chemotherapy) and 19 treatment-related deaths
(7 after alloHSCT, 3 after autoHSCT, and 9 after intensive che-
motherapy) after a median time measured from CR1 of 10.8 months
(range 4.4-61) and 15 months (range 1.2-144) occurred. This leads
to estimates of CIR and CID after 5 years of 3% (SE 3%) and 24%
(SE 8%) for alloHSCT, 27% (SE 11%) and 13% (SE 9%) for
autoHSCT, and 58% (SE 6%) and 10% (SE 4%) for intensive
chemotherapy, respectively.
Treatment after relapse
After relapse, 41 patients received intensive reinduction therapy,
1 patient had repetitive cycles of subcutaneous azacitidine, and 3
patients were treated with supportive care only. The second CR rate
(CR2) in all relapsed patients was 78% (35 of 45) and in those
receiving reinduction therapy (including azacitidine) 83% (35 of
42). Thirty-three patients received an alloHSCT (MRD n 5 11,
Table 1. Clinical and genetic characteristics of the total cohort and
according to applied postremission therapy
Total
cohort AlloHSCT AutoHSCT no HSCT P value
Characteristics n 5 124 n 5 32 n 5 20 n 5 72
Age, y
Median (range) 44 (16-60) 40 41 45 .12
Sex, no. (%)
Male 66 (53%) 21 (66%) 12 (60%) 33 (46%) .15
Female 58 (47%) 11 (34%) 8 (40%) 39 (54%)
WBC, x 109/l
Median (range) 32 (2-248) 16 (2-174) 36 (3-157) 34 (2-248) .23
Missing 1 1
Platelets, x109/l
Median (range) 41 (4-319) 39 (11.282) 47 (10-115) 40 (4-319) .42
Missing 3 3
Bone marrow
blasts, (%)
Median (range) 75 (7-100) 71 (7-99) 77 (31-99) 75 (25-100) .54
Missing 5 1 4
Type of AML,
no. (%)
De novo AML
M0 6 (5%) 1 (3%) 5 (7%) .24
M1 45 (36%) 10 (31%) 9 (45%) 26 (36%)
M2 54 (44%) 16 (50%) 6 (30%) 32 (44%)
M4 6 (5%) 2 (6%) 2 (10%) 2 (3%)
M5 2 (2%) 1 (3%) 1 (5%)
M6 1 (1%) 1 (5%)
Unclassified 1 (1%) 1 (1%)
Missing 9 (7%) 2 (6%) 1 (5%) 6 (9%)
Cytogenetics,
no, (%)
Normal
karyotype
92 (74%) 21 (66%) 14 (70%) 57 (79%) .32
Molecular
characteristics
no., (%)
FLT3-internal
tandem
duplications
11 (9%) 5 (16%) 1 (5%) 5 (7%) .38
NPM1 2 (2%) 1 (3%) 1 (1%) .67
Missing 1 1
Subheadings under “de novo AML” refer to French American British classifica-
tion subtypes.
WBC, white blood cell count; FLT3-ITD, FLT3 internal tandem duplication; neg,
negative; NPM1, nucleophosmin 1; WBC, white blood cell count; wt, wild-type.
Table 2. Abnormal karyotypes grouped according to leading
aberrations
Abnormal karyotypes
del(9q)
46,XY,del(9)(q12q31)[20]
46,XY,del(9)(q12q22),del(11)(q13q23)[21]
46,XY,del(9)(q12q34),del(11)(p11p15)[12]/46,XY[4]
46,XX,del(9)(q12q31;32)[26]/47,idem,121[2]/46,XX[7]
46,XX,del(9)(q1?2q3?2)[7]/46,XX[14]
46,XY,del(9)(q13q22)[22]
46,XY,del(9)(q13q22)[8]/46,XY[18]
46,XY,del(9)(q13q34)[2]/46,XY[19]
46,XY,del(7)(q22q32)[30]/46,XY,del(7)(q22q32),del(9)(q13q32)[2]
46,XX,del(9)(q21q22)
46,XX,del(9)(q22)[20]
46,XY,del(9)(q22q34)[13]/46,XY[7]
46,XY,del(9)(q22q34)[10]
46,XY,del(9)(q22q34)[2]/46,XY[17]
46,XY,del(9)(q22q34)[5]/47,XY,del(9)(q22q34),121[5]/46,XY[1]
46,XY,del(9)(q3?1)[2]/46,XY[38]
46,XX,del(9)(q3?1) or del(9)(q22q34)[11]/46,XX[19]
del(11q)
46,XX,del(11)(q13q25)[20]
46,XY,del(11)(q14q25)[3]/46,XY[60]
46,XY,del(11)(q21q23)[6]/46,XY[9]
46,XY,del(11)(q21q23)[7]
Other
45,X,-Y[14]
45,X,-Y[8]/46,XY[14]
46,XX,del(1)(p32p34)[21]
46,XX,del(7)(p13p15)[4]/46,XX[6]
46,XX,iso(17)(q10)[10]/46,XX[11]
47,XX,15[7]/46,XX[16]
47,XX,110[18]/46,XX[2]
47,XY,110[20]
47,XX,121[22]
47,XY,121[6]/46,XY[9]
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MUD n 5 19, haplo-identical donor n 5 3) after reinduction
therapy. At the time of alloHSCT, 28 patients achieved a second
CR2 after reinduction therapy, 4 had refractory disease, and 1
patient who relapsed after alloHSCT in CR1 received a stem-cell
boost from the same donor in CR2. Only 1 patient was treated
with an autoHSCT after relapse.
Survival analysis
The median follow-up time of patients still alive at the date of last
contact was 62 months. RFS and OS of the whole CEBPAdm patient
cohort after 5 years were 48% (95% CI, 38-57) and 63% (95% CI,
53-72), respectively. There was no difference in RFS (P5 .24) and
OS (P 5 .87) between patients exhibiting a normal karyotype and
those with intermediate-risk karyotypes (Table 2 and Figure 2).
Based on the Mantel-Byar test, including alloHSCT and autoHSCT
applied in CR1 as time dependent variables, RFS is signiﬁcantly
superior in patients receiving an HSCT (P, .001), with signiﬁcant
differences in favor of alloHSCT and autoHSCT as compared with
intensive chemotherapy (P , .001 and P 5 .019, respectively)
(Figure 3A). Multivariable analysis based on the Andersen-Gill
model including time-dependent postremission strategy, as well as
pretreatment values (Table 1) of white blood cells, platelets, bone
marrow (BM)-blast percentage, age, and karyotype (normal vs
abnormal) revealed that alloHSCT (hazard ratio [HR] 0.23; P, .001)
and autoHSCT (HR 0.37; P 5 .012) applied in CR1 independently
had a favorable prognostic impact regarding RFS (Table 3). However,
apparently due to a high second CR rate after salvage therapy, the
superior RFS after alloHSCT and autoHSCT did not translate into
a better OS in univariable analysis (P 5 .12) (Figure 3B) and
multivariable analyses (Table 4).
In 45 relapsed patients, OS measured from the date of relapse
was 46% (95% CI, 30-60) after 3 years (Figure 4). All patients
surviving more than 2 years after having ﬁrst relapsed had
undergone an alloHSCT (n 5 15, Figure 4).
Discussion
This report focuses on the evaluation of the clinical impact in
CEBPAdm patients of alloHSCT and autoHSCT in comparison
with intensive consolidation therapy in CR1, as well as focusing on
the impact of reinduction chemotherapy and alloHSCT after relapse.
To this attempt, we report on 124 adults with AML and a normal
karyotype or intermediate-risk karyotypes that harbor a CEBPAdm,
and are aged <60 years. Only 1 relapsed patient received an
autoHSCT in second CR and, therefore, we were not able to
evaluate the clinical impact of autoHSCT after relapse. Our results
clearly show that adult AML patients with the CEBPAdm genotype
signiﬁcantly beneﬁt from alloHSCT and autoHSCT in CR1 with
respect to RFS.
Figure 2. Influence of karyotype abnormalities on outcome. Kaplan-Meier plots
for the endpoints (A) RFS and (B) OS according to the karyotype (normal vs abnormal).
Figure 3. Influence of postremission treatment modality (alloHSCT, autoHSCT,
chemotherapy) on RFS (A) and OS (B). Simon-Makuch plots for the endpoints (A)
RFS and (B) OS according to type of postremission therapy.
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In recent years, it has become apparent that the favorable prognosis
of CEBPA gene mutations largely depends on the presence of the
CEBPAdm mutation type. At the molecular level AML with the
CEBPAdm compared with AML with CEBPA single mutation type
is associated with a lower frequency of coexisting NPM1 mutations
and FLT3 internal tandem duplications.6,8 Therefore, several inves-
tigators have recently suggested restricting the provisional WHO
2008 entity AML with CEBPA mutations to those with biallelic
mutations.4-8 As a direct consequence, the incidence of this AML
entity deﬁned by CEBPAdm decreases by about 40%5,8 to a
frequency of 3% to 6% of all AML cases. The low frequency of
CEBPAdm explains why comparative analyses with regard to
different postremission strategies, such as alloHSCT, autoHSCT,
and intensive chemotherapy, have not been performed so far. Beside
the recommended ELN risk category2 AML with CEBPA, we also
included the group of intermediate-risk karyotypes into the analyses
that includes approximately 30% of patients with chromosomal
abnormalities, in particular interstitial deletion 9q28 and 11q (Table 2)
instead of only patients with AML exhibiting a normal karyotype.
This approach is supported by the similar favorable outcome in
AML with CEBPAdm with and without normal karyotype in
univariable and multivariable analyses presented here (Figure 2).
Thus, these data add evidence that AML with CEBPAdm may be
regarded as a distinctive AML entity irrespective of additional
chromosomal abnormalities categorized within the cytogenetically
deﬁned intermediate-risk group.2
In the current analyses, we started with a total cohort of 5724
patients from which 5147 had a karyotype and, of those, the CEBPA
mutational status in 2983 was available. This large cohort was
required to ﬁnally achieve a sufﬁciently high number of 124 AML
patients with CEBPAdm in CR1 representing the basis of our
analyses. This approach underlines that large cooperative intergroup
meta-analyses are warranted to evaluate treatment effects with
acceptable statistical power in rare but clinically, highly relevant
patient subsets.
Our patients were treated in 7 different treatment trials, in part,
with changing therapeutic concepts over time. Thus, it is impossible
to apply the rigorous statistical standards for postremission treatment
allocation such as up-front or the so-called genetic randomization.
Instead, we applied statistical methods that have all in common,
that group allocation is implemented as a dynamic process over time
with a transition from the no-transplant group to the alloHSCT
or autoHSCT groups at the time point of HSCT. This approach
reduces the time-to-treatment bias and provides a solid statistical
methodology in situations in which simple Kaplan-Meier plots and
log-rank tests, as well as simple Cox regression models, are no
longer valid. However, to further reduce selection bias toward
HSCT in CR1, our univariable comparisons were complemented
by multivariable Andersen-Gill regression models addressing the
time-to-treatment bias27 again by including important pretreatment
characteristics.
By using methods that adjust for the time from CR to con-
solidation, we were able to show a clear superior RFS (P , .001)
in patients who received an alloHSCT or an autoHSCT in CR1 of
73% (95% CI, 54-86) and 60% (95% CI, 33-79) after 5 years,
respectively. These survival rates compare favorably to the RFS of
32% (95% CI, 21-45) in patients receiving intensive chemotherapy
only. A similarly good outcome has also been reported for other
AML entities categorized into the favorable ELN risk group, such
as core binding factor AML (CBF-AML), including AML with
inv(16) or t(16;16) and AML with t(8;21) after both alloHSCT and
autoHSCT.29,30 However, our results suggest that RFS after intensive
chemotherapy is substantially lower for AML with CEBPAdm as
compared with that of CBF-AML.31,32 Nevertheless, due to a high
second CR rate in reinduced relapsed patients with more than 80%
and a high proportion of patients proceeding to an alloHSCT after
relapse, the high relapse rate in the chemotherapy subgroup did not
translate into a signiﬁcant inferior OS. In fact, the high second CR
rate and favorable survival after relapse observed in the study
reported here are comparable to the survival probabilities observed
in AML with inv(16).31,32 Based on these data, AML with CEBPAdm
and AML with inv(16) or t(16;16) appear as 2 well-deﬁned excep-
tions from the general notion that after relapse a second CR is
rarely achieved.33 Therefore, instead of applying alloHSCT as the
compelling option in CR1, an alternative and not unreasonable
strategy would be to postpone the alloHSCT in CR1 and keep the
option of alloHSCT for salvage for the restricted fraction of
patients after relapse.33,34 Indeed, our data supports both strategies,
alloHSCT or autoHSCT in CR vs intensive chemotherapy as con-
solidation in CR1, and reinduction followed by alloHSCT in case
of relapse. Of note, the good results in our study with autoHSCT
are paralleled by those obtained in the core-binding factor AML29,30
indicating a speciﬁc chemo-sensitivity of these AMLs with favorable
risk according to the ELN recommendations2 to dose escalation
during consolidation therapy in CR1. Patients have to be well
informed about the risks and consequences of alloHSCT and
autoHSCT in CR1 regarding (1) short-term35 and long-term36
physical and psychological impairment; (2) infertility and a higher
rate of treatment-related mortality (eg, for alloHSCT, we ob-
served 24% at 5 years in our cohort); and (3) increased rates of
transplantation-related morbidity and mortality for alloHSCT when
the latter is performed after relapse.37 Besides the survival consid-
erations, there are other various arguments that would favor the choice
of an autoHSCT in CR1 as compared with alloHSCT. Given the
nearly identical RFS and OS rates after alloHSCT and autoHSCT,
the focus of outcome evaluations can be broadened to consider
quality of life aspects and late effects after transplantation, as well
as health economics, with a signiﬁcantly better quality of life and
Table 3. Andersen-Gill model for the end point RFS
RFS
Prognostic markers HR 95% CI P
Allogeneic HSCT 0.23 0.11-0.51 ,.001
Autologous HSCT 0.37 0.17-0.80 .012
Log10(WBC) 1.40 0.77-2.56 .27
Log10(platelets) 0.81 0.40-1.66 .57
% BM blasts (difference 10%) 0.94 0.82-1.08 .40
Age (difference of 10 y) 0.86 0.68-1.08 .20
Abnormal karyotype 0.73 0.38-1.40 .35
WBC, white blood cell count.
Table 4. Andersen-Gill model for the endpoint OS
RFS
Prognostic markers HR 95%-CI P
Allogeneic HSCT 0.50 0.21-1.17 .11
Autologous HSCT 0.57 0.23-1.40 .22
Log10(WBC) 1.34 0.64-2.80 .44
Log10(platelets) 0.95 0.40-2.26 .91
% BM blasts (difference 10%) 1.04 0.87-1.24 .69
Age (difference of 10 y) 1.08 0.82-1.42 .59
Abnormal karyotype 1.14 0.55-2.34 .73
WBC, white blood cell count.
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fewer late effects after autoHSCT compared with alloHSCT,38
whereas data on health economics are very system speciﬁc.39
In summary, our data provide novel clinical information that
may be useful for reﬁning the WHO 2008 classiﬁcation and the ELN
risk categorization for the provisional entity AML with CEBPAdm
in that beyond normal karyotype, all intermediate-risk cytogenetics
should be included. From a clinical perspective alloHSCT and
autoHSCT performed in CR1 were associated with comparatively
excellent RFS and OS, whereas the reduced rate of RFS in patients
receiving consolidation with intensive chemotherapy could be made
up after relapse by a high rate of second CR followed by alloHSCT.
Thus, the marker CEBPAdm develops with respect to RFS to a
predictive marker indicating superior RFS after autoHSCT and
alloHSCT, but remains a prognostic marker with respect to OS.
The pros and cons of alloHSCT and autoHSCT during CR1 or, as
an alternative option, alloHSCT after relapse, have to be carefully
considered and discussed with the patients with possible individual
adaptation of treatment recommendations while taking into account
the patient’s personal context.
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